CAL 3

Comparative Veterinary Pharmacokinetics

1. Introduction

  • In veterinary clinical practice, the sensitivity of a given animal species to a drug varies due to pharmacodynamic and pharmacokinetic differences.

  • In humans, individual differences are crucial, while in veterinary medicine, interspecies and inter-breed differences are more significant.

  • Pharmacokinetics is defined as the behavior of a drug in the body, covering aspects such as absorption, distribution, metabolism, and elimination (ADME).

  • For a drug to have a systemic effect, it needs to be absorbed and distributed to therapeutic concentration at its site of action.

  • If the target site is the gastrointestinal (GI) tract, absorption is unnecessary (in cases of oral administration).

  • There are significant variations in absorption, distribution, metabolism, and elimination processes across different animal species.

  • Due to pronounced interspecies variations, it is inappropriate to extrapolate pharmacokinetic data from humans or other animals, leading to hazardous consequences for certain drugs.

  • Nonetheless, the lack of pharmacokinetic data often necessitates using extrapolated human dosages empirically.

  • This chapter focuses on variations in the ADME process between different animal species, breeds, and ages.

2. Administration Routes in Veterinary Practice

  • Administration routes in veterinary medicine largely mirror those in human medicine, with minor distinctions.

  • Major routes of drug administration include:

    • Intravenous (IV): Fastest drug action; no absorption necessary.

    • IV bolus administration results in high plasma levels and rapid action.

    • Continuous IV infusion allows for controlled effects through steady-state plasma concentration.

    • Commonly used for anesthetics like propofol but also carries toxicity risks due to rapid entry into circulation.

    • Intramuscular (IM) and Subcutaneous (SC): Frequent in ruminants, swine, horses, dogs, cats, and rabbits.

    • Absorption rates are influenced by the administration route, vascularity of the site, drug concentration, and ionization.

    • Suprascapular IM injection leads to quicker absorption compared to other sites like the gluteal muscles.

    • Peak plasma concentrations typically achieved 20-40 minutes post-administration.

    • Oral (PO): Most common route; especially for food-producing animals.

    • Drugs can be administered via drinking water or mixed into feed in poultry and swine.

    • Various dosage forms include boluses, drenches, oral gels, pastes, tablets, capsules, solutions, and suspensions.

    • Topical: Raises pharmacokinetic issues; discussed in detail in the chapter on drug absorption.

    • Intramammary: Vital for treating and preventing mastitis in cattle.

    • Inhalational: Another route applicable to veterinary practice.

3. Absorption of Drugs

  • Absorption is necessary for drugs administered via any route except IV; the extent of absorption indicates bioavailability.

  • Bioavailability is defined as the ratio of the area under the curve (AUC) of the drug after extravascular vs. intravenous administration:
    F(bioavailability)=AUC<em>extravascularAUC</em>intravenousF (bioavailability) = \frac{AUC<em>{extravascular}}{AUC</em>{intravenous}}

  • Different types of bioavailability exist, including oral, IM, SC, and topical.

  • Greatest interspecies variations occur following oral administration; hence it is a focal point in this section.

  • Key factors affecting the extent and rate of absorption are:

    • Lipophilicity: Higher lipophilicity typically increases absorption.

    • Molecular weight: Influences ease of passage across membranes.

    • Degree of ionization: Affects solubility at the site of administration.

  • Weak acids (e.g., NSAIDs) are more non-ionized in the acidic stomach environment improving their absorption in the proximal GI tract.

    • These acids exhibit lower Tmax (time to reach maximum plasma concentration).

  • Weak bases, being ionized in the stomach, usually have higher Tmax values.

  • First pass effect can significantly modify oral bioavailability as many drugs like lidocaine and morphine are inactivated in the liver upon first exposure.

  • Parenteral or rectal administration routes can bypass the first pass metabolism.

  • Pharmaceutical formulations can alter absorption rates, delaying or prolonging effects.

    • Examples include modified-release tablets and depot injections.

  • Certain physical interactions with food can impede absorption (e.g., tetracyclines forming insoluble complexes with calcium).

  • Diseases causing increased gastrointestinal motility can lead to decreased absorption efficacy.

    • Example: In canine or feline parvovirosis leading to increased absorption rates of certain previously unabsorbed substances.

3.1 Differences in Oral and Parenteral Absorption among Animal Species

  • Understanding monogastric versus ruminant, herbivore, omnivore, and carnivore digestive systems is vital for comparative pharmacokinetics.

    • The GI tract length and volume in ruminants (like cows) slow down drug absorption significantly in comparison to non-ruminant species (like dogs).

  • For example, benzimidazole anthelminthics (e.g., albendazole) can provide prolonged action in ruminants, while dogs and cats typically require multiple doses.

  • The oral bioavailability of amoxicillin varies:

    • Horses: 5%

    • Swine: 28-33%

    • Poultry: 59-68%

    • Dogs & Cats: 60-80%

  • Notably, some antibiotics show variable efficacy due to decreased absorption in specific species unless formulated properly.

  • For ruminants, due to the extensive ruminal fluid volume, drug efficacy may be diminished unless specifically formulated for sustained release.

3.2 Percutaneous Absorption after Topical Administration

  • Absorption occurs in three phases:

    1. The drug must be dissolved.

    2. It must penetrate the stratum corneum and epithelial layer.

    3. It ultimately needs to enter the bloodstream.

  • Lipophilicity is a critical factor for effective percutaneous absorption.

  • Certain substances, including some ectoparasiticides and glucocorticoids, have high percutaneous absorption rates but are influenced by skin thickness and integrity.

  • Inflammation or skin damage can enhance absorption, previously noted in feline reactions to certain spot-on products containing methyl- or ethyl-based derivatives.

3.3 Intranasal Absorption

  • Intranasal drug application is less common but growing in veterinary practice; advantageous due to avoiding first-pass metabolism.

  • Example: Oxytocin for inducing labor in swine.

  • Other drugs like diazepam, used as an anticonvulsant, show promising nasal bioavailability of 41–42% in dogs, providing crucial alternatives for status epilepticus.

3.4 Intramammary Absorption

  • Commonly used for antibiotics and anti-inflammatory drugs in dairy cattle for treating mastitis.

  • Conditions promoting inflammation enhance absorption rates in mammary tissues compared to healthy states.

4. Drug Distribution

  • Post-absorption, drugs are distributed throughout the body, which varies based on tissue access and blood flow rates.

  • Factors affecting this distribution include lipophilicity, molecular weight, ionization, and local blood flow rates.

  • The volume of distribution (Vd) quantifies drug distribution in plasma: V</em>d=A(t)CpV</em>d = \frac{A(t)}{C_p} where:

    • $A(t)$ = amount of drug in the body

    • $C_p$ = plasma concentration

  • A high $V_d$ indicates extensive distribution beyond plasma concentrations, as seen with highly lipophilic drugs that accumulate significantly in specific tissues.

5. Drug Metabolism

  • Metabolism processes involve modifying the drug to enhance excretion potential; primarily through biotransformation.

  • Biotransformation occurs in two phases:

    • Phase I (non-synthetic): Involves chemical alterations that prepare the drug for conjugation.

    • Phase II (synthetic): Conjugation with polar substances that enhances water solubility.

  • Significant species variations occur in drug metabolism, particularly in different Phase II conjugation pathways.

6. Drug Excretion

  • Elimination is achieved through metabolism and primary excretion pathways (mostly renal).

  • Elimination kinetics typically follow first-order processes but can transition to zero-order when excretion processes become saturated complicating the medication regimens especially in animals susceptible to toxicity.

7. Acknowledgement

  • Expresses gratitude to Dr. József Lehel and Dr. Melinda Donka-Jerzsele for their expert guidance throughout the chapter.